Diagnosis and therapeutic management in a patient with type 2B-like acquired von Willebrand syndrome

Blood Coagulation and Fibrinolysis

Volumn 22, Issue 2, 2011, Pages 144-147

  Karger, Ralf ^a,b   Weippert Kretschmer, Monika ^c   Budde, Ulrich ^d   Kretschmer, Volker ^b  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b Praxis für Transfusionsmedizin ^*

^c Medizinisches Labor Rostock   (Germany)

^d Medilys Laborgesellschaft mbH   (Germany)

Author keywords

acquired von Willebrand syndrome; monoclonal gammopathy; von Willebrand disease type 2B

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE; DESMOPRESSIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ADULT; ANAMNESIS; ARTICLE; CASE REPORT; CHOLECYSTECTOMY; CHRONIC CHOLECYSTITIS; HUMAN; LABORATORY TEST; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; PARTIAL THROMBOPLASTIN TIME; POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; VON WILLEBRAND DISEASE;

ADULT; AUTOANTIBODIES; BLEEDING TIME; CHOLECYSTECTOMY, LAPAROSCOPIC; COLLAGEN; DEAMINO ARGININE VASOPRESSIN; DIAGNOSIS, DIFFERENTIAL; EXONS; FACTOR VII; FACTOR VIII; HUMANS; MALE; PARAPROTEINEMIAS; PLATELET AGGREGATION; PROTEIN BINDING; RECOMBINANT PROTEINS; RISTOCETIN; SEQUENCE ANALYSIS; SYNDROME; VON WILLEBRAND DISEASE, TYPE 2; VON WILLEBRAND FACTOR;

EID: 79951677040     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e328342486a     Document Type: Article

References (20)

1. Veyradier A, Jenkins CSP, Fressinaud E, Meyer D. Acquired von Willebrand syndrome: from pathophysiology to management. Thromb Haemost 2000; 84:175-182. (Pubitemid 30601460)
2. Mohri H, Motomura S, Kanamori H, Matsuzaki M, Watanabe S, Maruta A, et al. Clinical significance of inhibitors in acquired von Willebrand syndrome. Blood 1998; 91:3623-3629. (Pubitemid 28225728)
3. Shinagawa A, Kojima H, Berndt MC, Kaneko S, Suzukawa K, Hasegawa Y, et al. Characterization of a myeloma patient with a life-threatening hemorrhagic diathesis: presence of a lambda dimer protein inhibiting shear-induced platelet aggregation by binding tothe AIdomainof von Willebrand factor. Thromb Haemost 2005; 93:889-896. (Pubitemid 40691546)
4. Dong J-F, Berndt MC, Schade A, McIntire LV, Andrews RK, López JA. Ristocetin-dependent, but not botrocetin-dependent, binding of von Willebrand factor to the platelet glycoprotein Ib-IX-V complex correlates with shear-dependent interactions. Blood2001; 97:162-168. (Pubitemid 32061256)
5. Ruggeri ZM. Von Willebrand factor: looking back and looking forward. Thromb Haemost 2007; 98:55-62. (Pubitemid 47078779)
6. Kratzer MA, Born GV. Simulation of primary haemostasis in vitro. Haemostasis 1985; 15:357-362. (Pubitemid 16206083)
7. Federici AB. Clinical diagnosis of von Willebrand disease. Haemophilia 2004; 10 (Suppl 4):169-176. (Pubitemid 40045438)
8. Budde U, Schneppenheim R, Plendl H, Dent J, Ruggeri ZM, Zimmermann TS. Luminographicdetection of von Willebrand factormultimers in agarose gels and on nitrocellulose membranes. Thromb Haemost 1990; 63:312-315. (Pubitemid 20128202)
9. Favaloro EJ, Lloyd J, Rowell J, Baker R, Richard K, Kershaw G, et al. Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF(High Purity)] in people with von Willebrand disorder. A randomised cross-over, multicentre study. Thromb Haemost2007; 97:922-930. (Pubitemid 46939204)
10. SzántóT,Schlammadinger A, Salles I, Pareyn I, Vauterin S, HársfalviJ, etal. Type 2B von Willebrand disease in seven individuals from three different families: phenotypic and genotypic characterization. Thromb Haemost 2007; 98:251-254. (Pubitemid 47074204)
11. Drouin J, Lillicrap DP, Izaguirre CA, Sutherland M, Windsor S, Benford K, etal. Absence of a bleeding tendency in severe acquired von Willebrand's disease. Am J Clin Pathol1989; 92:471-478.
12. Sadler JE. A revised classification of von Willebrand disease. Thromb Haemost 1994; 71:520-525.
13. Fressinaud E, Veyradier A, Truchaud F, Martin I, Boyer-Neumann C, Meyer D. Screening for von Willebrand disease with a new analyzer using high shear stress: a study of 60 cases. Blood 1998; 91:1325-1331. (Pubitemid 28086886)
14. Kretschmer V, Weippert-Kretschmer M. Determination and treatment of disordersofprimary haemostasis:experiencewith routineapplication of the in vitro bleeding test. Hämostaseologie 1999; 19:168-175.
15. Karger R, Donner-Banzhoff N, Müller H-H, Kretschmer V, Hunink M. Diagnostic performance of the platelet function analyzer (PFA-100) for the detection of disorders of primary haemostasis in patients with a bleeding history: a systematic review and meta-analysis. Platelets 2007; 18:249-260. (Pubitemid 46854816)
16. Sadler JE, Blinder M. Von Willebrand disease: diagnosis, classification and treatment. In: Colman RW, Marder VJ, Clowes AW, George GN, Goldhaber SZ, editors. Hemostasis and thrombosis. Basic principles and clinicalpractice, 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2006 pp. 905-921.
17. Smaradottir A, Bona R. A case of acquired von Willebrand syndrome successfully treated with recombinant factor VIIa during thyroidectomy (case report). Thromb Haemost 2004; 92:666-667. (Pubitemid 39248026)
18. Depraetere H, Ajzenberg N, Girma J-P, Lacombe C, Meyer D, Deckmyn H, et al. Platelet aggregation induced by a monoclonal antibody to the A1 domain of von Willebrand factor. Blood 1998; 91:3792-3799. (Pubitemid 28225747)
19. Kumar S, Pruthi RK, Nichols WL. Acquired von Willebrand's syndrome: a single institution experience. Am J Hematol 2003; 72:243-247. (Pubitemid 36383974)
20. Castaman G, Rodeghiero F. Desmopressin and type II B von Willebrand disease. Haemophilia 1996; 2:73-77. (Pubitemid 26127477)